验证巴韦诺VI标准及扩展的巴韦诺VI标准以识别与MAFLD相关的代偿期肝硬化患者中的高危静脉曲张。 - Suppr

Validation of Baveno VI and expanded Baveno VI criteria to identify high-risk varices in patients with MAFLD-related compensated cirrhosis.

作者信息

Zheng Kenneth I, Liu Chuan, Li Jia, Zhao Lili, Zheng Ming-Hua, Wang Fengmei, Qi Xiaolong

机构信息

Department of Gastroenterology and Hepatology, Tianjin Second People's Hospital, Tianjin, China; MAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.

CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China.

出版信息

J Hepatol. 2020 Dec;73(6):1571-1573. doi: 10.1016/j.jhep.2020.06.042. Epub 2020 Sep 21.

DOI:10.1016/j.jhep.2020.06.042

PMID:32972730

Abstract

摘要

相似文献

Validation of Baveno VI and expanded Baveno VI criteria to identify high-risk varices in patients with MAFLD-related compensated cirrhosis.

J Hepatol. 2020 Dec;73(6):1571-1573. doi: 10.1016/j.jhep.2020.06.042. Epub 2020 Sep 21.

Noninvasive assessment oesophageal varices: impact of the Baveno VI criteria.

Curr Opin Gastroenterol. 2022 May 1;38(3):206-215. doi: 10.1097/MOG.0000000000000824. Epub 2022 Mar 2.

Validation of Baveno VI and Expanded-Baveno VI Criteria for predicting gastroesophageal varices in patients with alcoholic and non-alcoholic fatty liver disease.

Acta Gastroenterol Belg. 2022 Apr-Jun;85(2):321-329. doi: 10.51821/88.2.9553.

Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis.

J Hepatol. 2018 Oct;69(4):878-885. doi: 10.1016/j.jhep.2018.05.019. Epub 2018 May 24.

Validation of original, expanded Baveno VI, and stepwise & platelet-MELD criteria to rule out varices needing treatment in compensated cirrhosis from various etiologies.

Ann Hepatol. 2020 Mar-Apr;19(2):209-213. doi: 10.1016/j.aohep.2019.08.005. Epub 2019 Sep 25.

Baveno criteria perform better than expanded Baveno and Rete Sicilia Selezione Terapia-Hepatitis C virus criteria for predicting varices needing treatment.

Indian J Gastroenterol. 2021 Dec;40(6):590-597. doi: 10.1007/s12664-020-01141-9. Epub 2021 May 15.

Utility of different Baveno criteria to detect esophageal varices irrespective of their size in patients with compensated cirrhosis.

Indian J Gastroenterol. 2024 Jun;43(3):609-615. doi: 10.1007/s12664-023-01458-1. Epub 2023 Oct 16.

Validation of the EVendo score for the prediction of varices in cirrhotic patients.

Saudi J Gastroenterol. 2022 Sep-Oct;28(5):378-384. doi: 10.4103/sjg.sjg_624_21.

A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease.

J Hepatol. 2018 Aug;69(2):308-317. doi: 10.1016/j.jhep.2018.04.023. Epub 2018 May 3.

Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis.

J Hepatol. 2021 Mar;74(3):584-592. doi: 10.1016/j.jhep.2020.09.034. Epub 2020 Oct 8.

引用本文的文献

Noninvasive model based on liver and spleen stiffness for predicting clinical decompensation in patients with cirrhosis.

World J Gastroenterol. 2025 Sep 7;31(33):107408. doi: 10.3748/wjg.v31.i33.107408.

Portal hypertension in patients with nonalcoholic fatty liver disease: Current knowledge and challenges.

World J Gastroenterol. 2024 Jan 28;30(4):290-307. doi: 10.3748/wjg.v30.i4.290.

6-mm shunt transjugular intrahepatic portosystemic shunt in patients with severe liver atrophy and variceal bleeding.

Eur Radiol. 2024 Jul;34(7):4697-4707. doi: 10.1007/s00330-023-10346-3. Epub 2023 Nov 25.

Non-invasive model for predicting high-risk esophageal varices based on liver and spleen stiffness.

World J Gastroenterol. 2023 Jul 7;29(25):4072-4084. doi: 10.3748/wjg.v29.i25.4072.

Correlation between serum liver fibrosis markers and early gastroesophageal varices among patients with compensated liver cirrhosis: a cross-sectional analysis.

BMC Gastroenterol. 2022 Dec 12;22(1):515. doi: 10.1186/s12876-022-02546-w.

Modified and alternative Baveno VI criteria based on age for ruling out high-risk varices in patients with compensated cirrhosis.

Hepatol Int. 2022 Aug;16(4):936-943. doi: 10.1007/s12072-022-10359-y. Epub 2022 Jun 21.

The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Saudi J Gastroenterol. 2022 Jan-Feb;28(1):3-20. doi: 10.4103/sjg.sjg_357_21.

Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease.

J Gastroenterol Hepatol. 2022 May;37(5):795-811. doi: 10.1111/jgh.15787. Epub 2022 Feb 8.

When a new definition overhauls perceptions of MAFLD related cirrhosis care.

Hepatobiliary Surg Nutr. 2020 Dec;9(6):801-804. doi: 10.21037/hbsn-20-725.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Validation of Baveno VI and expanded Baveno VI criteria to identify high-risk varices in patients with MAFLD-related compensated cirrhosis.

作者信息

Zheng Kenneth I, Liu Chuan, Li Jia, Zhao Lili, Zheng Ming-Hua, Wang Fengmei, Qi Xiaolong

机构信息

CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China.

出版信息

J Hepatol. 2020 Dec;73(6):1571-1573. doi: 10.1016/j.jhep.2020.06.042. Epub 2020 Sep 21.

DOI:10.1016/j.jhep.2020.06.042

PMID:32972730

Abstract

摘要

相似文献

Validation of Baveno VI and expanded Baveno VI criteria to identify high-risk varices in patients with MAFLD-related compensated cirrhosis.

J Hepatol. 2020 Dec;73(6):1571-1573. doi: 10.1016/j.jhep.2020.06.042. Epub 2020 Sep 21.

Noninvasive assessment oesophageal varices: impact of the Baveno VI criteria.

Curr Opin Gastroenterol. 2022 May 1;38(3):206-215. doi: 10.1097/MOG.0000000000000824. Epub 2022 Mar 2.

Validation of Baveno VI and Expanded-Baveno VI Criteria for predicting gastroesophageal varices in patients with alcoholic and non-alcoholic fatty liver disease.

Acta Gastroenterol Belg. 2022 Apr-Jun;85(2):321-329. doi: 10.51821/88.2.9553.

Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis.

J Hepatol. 2018 Oct;69(4):878-885. doi: 10.1016/j.jhep.2018.05.019. Epub 2018 May 24.

Validation of original, expanded Baveno VI, and stepwise & platelet-MELD criteria to rule out varices needing treatment in compensated cirrhosis from various etiologies.

Ann Hepatol. 2020 Mar-Apr;19(2):209-213. doi: 10.1016/j.aohep.2019.08.005. Epub 2019 Sep 25.

Baveno criteria perform better than expanded Baveno and Rete Sicilia Selezione Terapia-Hepatitis C virus criteria for predicting varices needing treatment.

Indian J Gastroenterol. 2021 Dec;40(6):590-597. doi: 10.1007/s12664-020-01141-9. Epub 2021 May 15.

Utility of different Baveno criteria to detect esophageal varices irrespective of their size in patients with compensated cirrhosis.

Indian J Gastroenterol. 2024 Jun;43(3):609-615. doi: 10.1007/s12664-023-01458-1. Epub 2023 Oct 16.

Validation of the EVendo score for the prediction of varices in cirrhotic patients.

Saudi J Gastroenterol. 2022 Sep-Oct;28(5):378-384. doi: 10.4103/sjg.sjg_624_21.

A combined model based on spleen stiffness measurement and Baveno VI criteria to rule out high-risk varices in advanced chronic liver disease.

J Hepatol. 2018 Aug;69(2):308-317. doi: 10.1016/j.jhep.2018.04.023. Epub 2018 May 3.

Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis.

J Hepatol. 2021 Mar;74(3):584-592. doi: 10.1016/j.jhep.2020.09.034. Epub 2020 Oct 8.

引用本文的文献

Noninvasive model based on liver and spleen stiffness for predicting clinical decompensation in patients with cirrhosis.

World J Gastroenterol. 2025 Sep 7;31(33):107408. doi: 10.3748/wjg.v31.i33.107408.

Portal hypertension in patients with nonalcoholic fatty liver disease: Current knowledge and challenges.

World J Gastroenterol. 2024 Jan 28;30(4):290-307. doi: 10.3748/wjg.v30.i4.290.

6-mm shunt transjugular intrahepatic portosystemic shunt in patients with severe liver atrophy and variceal bleeding.

Eur Radiol. 2024 Jul;34(7):4697-4707. doi: 10.1007/s00330-023-10346-3. Epub 2023 Nov 25.

Non-invasive model for predicting high-risk esophageal varices based on liver and spleen stiffness.

World J Gastroenterol. 2023 Jul 7;29(25):4072-4084. doi: 10.3748/wjg.v29.i25.4072.

Correlation between serum liver fibrosis markers and early gastroesophageal varices among patients with compensated liver cirrhosis: a cross-sectional analysis.

BMC Gastroenterol. 2022 Dec 12;22(1):515. doi: 10.1186/s12876-022-02546-w.

Modified and alternative Baveno VI criteria based on age for ruling out high-risk varices in patients with compensated cirrhosis.

Hepatol Int. 2022 Aug;16(4):936-943. doi: 10.1007/s12072-022-10359-y. Epub 2022 Jun 21.

The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease.

Saudi J Gastroenterol. 2022 Jan-Feb;28(1):3-20. doi: 10.4103/sjg.sjg_357_21.

Malaysian Society of Gastroenterology and Hepatology consensus statement on metabolic dysfunction-associated fatty liver disease.

J Gastroenterol Hepatol. 2022 May;37(5):795-811. doi: 10.1111/jgh.15787. Epub 2022 Feb 8.

When a new definition overhauls perceptions of MAFLD related cirrhosis care.

Hepatobiliary Surg Nutr. 2020 Dec;9(6):801-804. doi: 10.21037/hbsn-20-725.

Validation of Baveno VI and expanded Baveno VI criteria to identify high-risk varices in patients with MAFLD-related compensated cirrhosis.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Validation of Baveno VI and expanded Baveno VI criteria to identify high-risk varices in patients with MAFLD-related compensated cirrhosis.

作者信息

机构信息

出版信息

相似文献

引用本文的文献